Workflow
Lishengpharma(002393)
icon
Search documents
力生制药:预计半年度净利增长222.42%—246.85% 培哚普利氨氯地平片国内上市许可申请获批
7月15日,力生制药(002393)发布2025年半年度业绩预告,预计上半年公司实现净利3.3亿元—3.55亿 元,同比增长222.42%—246.85%。对于业绩大幅增长,公告表示,公司克服产品降价因素,积极开拓 市场,扩大产品销量,加之天士力(600535)集团分红的积极影响,均对业绩有所贡献。 2024年11月,公司精氨酸培哚普利原料药率先获批,是公司"原料+制剂"战略的关键落子,标志着力生 制药在心脑血管治疗领域实现"原料自主化+剂型差异化+生产规模化"的全链条突破,将有望为公司打 开增量市场空间,增加新的利润增长点。(燕云) 7月15日晚间,力生制药发布公告,由力生制药研发的两个规格的培哚普利氨氯地平片近日获得国家药 品监督管理局上市许可批准,其中培哚普利氨氯地平片(Ⅰ)为国内第二家、培哚普利氨氯地平片(Ⅲ)为 国内第四家。按化学药品新注册分类批准的仿制药,均视同通过一致性评价。培哚普利氨氯地平片(Ⅰ) 规格为每片含精氨酸培哚普利5mg、苯磺酸氨氯地平5mg(按C20H25ClN2O5计),力生制药为该规格国内 第一家仿制药获批企业。力生制药表示,培哚普利氨氯地平片的获批上市将进一步丰富公司产品结构 ...
力生制药(002393) - 关于药品培哚普利氨氯地平片(Ⅰ)和培哚普利氨氯地平片(Ⅲ)通过上市许可申请的公告
2025-07-15 08:00
培哚普利氨氯地平片(Ⅰ)和培哚普利氨氯地平片(Ⅰ)适应症: 关于药品培哚普利氨氯地平片(Ⅰ)和培哚普利氨氯地平 片(Ⅲ)通过上市许可申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 一、概况 近日,天津力生制药股份有限公司(以下简称"本公司")收到国家药品监督管理局 颁发的关于培哚普利氨氯地平片(Ⅰ)(规格:每片含精氨酸培哚普利5mg和苯磺酸氨 氯地平(按C20H25ClN2O5计)5mg)的《药品注册证书》(批件编号:2025S02104); 培哚普利氨氯地平片(Ⅰ)(规格:每片含精氨酸培哚普利10mg和苯磺酸氨氯地平(按 C20H25ClN2O5计)5mg)的《药品注册证书》(批件编号:2025S02103),上述药品 通过药品上市许可申请。 | 药品名称 | 培哚普利氨氯地平片(Ⅰ) | 培哚普利氨氯地平片(Ⅲ) | | --- | --- | --- | | 剂 型 | 片 剂 | | | 规 格 | 每片含精氨酸培哚普利5mg和苯 | 每片含精氨酸培哚普利10mg和苯 | | | 磺酸氨氯地平(按C20H25ClN2O5计) | 磺酸氨氯地 ...
多重利好共振、推升经营 力生制药25H1净利同比预增222.42%-246.85%
Quan Jing Wang· 2025-07-15 00:45
Core Viewpoint - Lisheng Pharmaceutical (002393.SZ) is expected to report significant growth in net profit for the first half of 2025, driven by market expansion and product volume increase, alongside investment income from its subsidiary Tianjin Central Pharmaceutical [1][2] Group 1: Financial Performance - For the first half of 2025, the company anticipates a net profit attributable to shareholders of between 330 million to 355 million yuan, representing a year-on-year increase of 222.42% to 246.85% [1] - The net profit after excluding non-recurring gains and losses is projected to be between 100 million to 115 million yuan, showing a year-on-year growth of 0.83% to 15.95% [1] Group 2: Market Strategy - The company has overcome the challenges posed by product price reductions by actively expanding its market presence and increasing product sales [1] - Lisheng Pharmaceutical has intensified its research and development efforts in the chronic disease sector, particularly focusing on cardiovascular products, and has accelerated the launch of new products [1] Group 3: Dividend Impact - The company will receive a cash dividend of 304 million yuan from its wholly-owned subsidiary Tianjin Central Pharmaceutical, based on its 12.15% stake in Tianshili Biological [1] Group 4: Competitive Position - Industry experts highlight that Lisheng Pharmaceutical demonstrates strong risk resistance due to its brand strength, cost control capabilities, and precise strategic positioning amid the normalization of centralized procurement and increasing industry differentiation [2] - The company is expected to maintain high growth in the second half of the year, with annual profitability potentially exceeding expectations due to the gradual realization of its innovative drug pipeline and new product launches [2]
力生制药(002393) - 2025 Q2 - 季度业绩预告
2025-07-14 08:00
本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间:2025年1月1日-2025年6月30日 2、预计的业绩:□亏损□扭亏为盈 ☑同向上升 □同向下降 3、业绩预告为区间 证券代码:002393 证券简称:力生制药 公告编号:2025-046 天津力生制药股份有限公司 2025年半年度业绩预告 三、业绩变动原因说明 公司克服产品降价因素,积极开拓市场,扩大产品销量,加之天士力集团分红影 响,归属于上市公司股东的净利润同比增幅较大。 四、其他相关说明 本次业绩预告是公司财务部门初步核算的结果,具体财务数据以公司披露的 2025年半年度报告为准。敬请广大投资者谨慎决策,注意投资风险。 | 目 项 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东的 | 盈利:33000-35500 万元 | 盈利:10235 万元 | | 净利润 | 比上年同期上升:222.42%-246.85% | | | 扣除非经常性损益后的 | 盈利:10000-11500 万元 | 盈利:9918 万元 | ...
力生制药:预计上半年净利润同比上升222.42%-246.85%
news flash· 2025-07-14 07:59
力生制药(002393)公告,预计2025年上半年净利润为33000-3.55亿元,比上年同期的1.02亿元上升 222.42%-246.85%。 ...
天津力生制药股份有限公司 关于补缴税款的公告
Group 1 - The company, Tianjin Lifescience Pharmaceutical Co., Ltd., is required to pay a total of approximately 35.11 million yuan in tax and late fees due to local tax inspections and self-examinations [1] - The breakdown of the payment includes approximately 30.88 million yuan for income tax and late fees, and 4.23 million yuan for value-added tax and late fees [1] - All tax payments and late fees have been fully paid by the company [1] Group 2 - The tax payment and late fees will be recorded in the company's 2025 financial results, expected to reduce the net profit attributable to shareholders by 35.11 million yuan [2] - The management of the company is taking this matter seriously and will enhance tax management and conduct ongoing tax training to protect the interests of the company and its shareholders [2]
力生制药(002393) - 关于补缴税款的公告
2025-06-27 07:45
证券代码:002393 证券简称:力生制药 公告编号:2025-045 天津力生制药股份有限公司 关于补缴税款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司(以下简称"公司")根据当地税务检查和企业自查情况, 需补缴税款及滞纳金共计约3,511万元。现将有关情况公告如下: 一、基本情况 根据国家税务总局天津市西青税务局对公司检查情况,以及公司自查情况,公司应补 缴税款及滞纳金等共计约3,511万元,其中:需补缴所得税及滞纳金3,088万元,需补缴增 值税及滞纳金423万元,本次不涉及行政处罚。上述税款及滞纳金目前已全部缴纳完毕。 二、对公司的影响及风险提示 根据《企业会计准则第28号--会计政策、会计估计变更和差错更正》,上述补缴税款及 滞纳金事项不属于前期会计差错,不涉及前期财务数据追溯调整。公司补缴的税款及滞纳 金将计入2025年当期损益,预计将减少公司2025年度归属于上市公司股东的净利润3,511 万元,具体影响金额最终以会计师事务所审计数据为准。 公司管理层对上述事项高度重视,将进一步加强税务管理,持续开展税务专业培 ...
力生制药:补缴税款及滞纳金约3511万元
news flash· 2025-06-27 07:44
力生制药(002393)公告,根据当地税务检查和企业自查,需补缴税款及滞纳金共计约3511万元。其 中,需补缴所得税及滞纳金3088万元,需补缴增值税及滞纳金423万元。本次不涉及行政处罚。上述税 款及滞纳金目前已全部缴纳完毕。补缴的税款及滞纳金将计入2025年当期损益,预计将减少公司2025年 度归属于上市公司股东的净利润3511万元。 ...
力生制药(002393) - 关于使用闲置自有资金进行现金管理的进展公告
2025-06-19 08:00
证券代码:002393 证券简称:力生制药 公告编号:2025-044 天津力生制药股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司(以下简称"公司")于2025年3月19日召开第七届董事 会第五十次会议、2025年4月11日召开2024年度股东大会,审议通过了《关于公司2025年 使用闲置自有资金进行现金管理额度的议案》,同意公司使用额度不超过人民币10亿元闲 置自有资金购买安全性高、流动性好、主要大型商业银行或证券机构发行的短期理财产品, 包括但不限于通过银行、证券等专业理财机构购买的理财产品,期限不超过股东大会批准 之日起12个月,在上述额度及期限范围内资金滚动使用。具体内容详见公司于2025年3月 21日在巨潮资讯网(www.cninfo.com.cn)披露的《关于公司2025年使用闲置自有资金进行 现金管理额度的公告》(公告编号:2025-024)。 一、本次进行现金管理购买理财产品情况 公司以自有资金共计5,000万元人民币在兴业银行股份有限公司天津分行(以下简称"兴 ...
每周股票复盘:力生制药(002393)使用闲置资金及募集资金购买理财产品
Sou Hu Cai Jing· 2025-06-13 18:55
Core Viewpoint - Lisheng Pharmaceutical (002393) has seen a significant increase in stock price, reaching a nearly one-year high, and is actively managing idle funds through short-term financial products [1][2]. Company Stock Performance - As of June 13, 2025, Lisheng Pharmaceutical's stock closed at 22.11 yuan, up 13.79% from the previous week [1]. - The stock reached a peak of 22.11 yuan during the week and a low of 19.5 yuan [1]. - The company's current market capitalization is 5.698 billion yuan, ranking 83rd out of 150 in the chemical pharmaceutical sector and 2608th out of 5150 in the A-share market [1]. Company Announcements - Lisheng Pharmaceutical announced the use of up to 1 billion yuan of idle self-owned funds for cash management, investing in short-term financial products with a maturity of no more than 12 months [2]. - The company has invested 50 million yuan in financial products from Industrial Bank, including 10 million yuan in a flexible income product and 40 million yuan in a stable income product, with expected yields of approximately 2% and 2.2% respectively [2]. - The total amount of idle self-owned funds invested in financial products as of the announcement date is 639 million yuan, which is within the authorized limit [2]. Fund Management - Lisheng Pharmaceutical also plans to use up to 600 million yuan of idle raised funds for cash management, investing in short-term financial products with a maturity of no more than 12 months [2]. - The company has invested 50 million yuan in structured deposits from Industrial Bank, with an expected annual yield of 1.20%-1.80% [2]. - The total amount of idle raised funds invested in financial products as of the announcement date is 85 million yuan, also within the approved limit [2].